These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31334542)

  • 1. Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function.
    Ramezanpour M; Schmidt ML; Bodnariuc I; Kulkarni JA; Leung SSW; Cullis PR; Thewalt JL; Tieleman DP
    Nanoscale; 2019 Aug; 11(30):14141-14146. PubMed ID: 31334542
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Algarni A; Pilkington EH; Suys EJA; Al-Wassiti H; Pouton CW; Truong NP
    Biomater Sci; 2022 May; 10(11):2940-2952. PubMed ID: 35475455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA.
    Kulkarni JA; Darjuan MM; Mercer JE; Chen S; van der Meel R; Thewalt JL; Tam YYC; Cullis PR
    ACS Nano; 2018 May; 12(5):4787-4795. PubMed ID: 29614232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pH-dependent structural transitions in cationic ionizable lipid mesophases are critical for lipid nanoparticle function.
    Philipp J; Dabkowska A; Reiser A; Frank K; Krzysztoń R; Brummer C; Nickel B; Blanchet CE; Sudarsan A; Ibrahim M; Johansson S; Skantze P; Skantze U; Östman S; Johansson M; Henderson N; Elvevold K; Smedsrød B; Schwierz N; Lindfors L; Rädler JO
    Proc Natl Acad Sci U S A; 2023 Dec; 120(50):e2310491120. PubMed ID: 38055742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.
    Lee JB; Zhang K; Tam YY; Tam YK; Belliveau NM; Sung VY; Lin PJ; LeBlanc E; Ciufolini MA; Rennie PS; Cullis PR
    Int J Cancer; 2012 Sep; 131(5):E781-90. PubMed ID: 22095615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHARMM-GUI Membrane Builder for Lipid Nanoparticles with Ionizable Cationic Lipids and PEGylated Lipids.
    Park S; Choi YK; Kim S; Lee J; Im W
    J Chem Inf Model; 2021 Oct; 61(10):5192-5202. PubMed ID: 34546048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach.
    Terada T; Kulkarni JA; Huynh A; Chen S; van der Meel R; Tam YYC; Cullis PR
    Langmuir; 2021 Jan; 37(3):1120-1128. PubMed ID: 33439022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acidic pH-induced changes in lipid nanoparticle membrane packing.
    Koitabashi K; Nagumo H; Nakao M; Machida T; Yoshida K; Sakai-Kato K
    Biochim Biophys Acta Biomembr; 2021 Aug; 1863(8):183627. PubMed ID: 33901441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHARMM-GUI Membrane Builder for Lipid Nanoparticles with Ionizable Cationic Lipids and PEGylated Lipids.
    Park S; Choi YK; Kim S; Lee J; Im W
    bioRxiv; 2021 Jun; ():. PubMed ID: 34189527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
    Suzuki Y; Ishihara H
    Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
    Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
    J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization-Enhanced NMR Spectroscopy.
    Viger-Gravel J; Schantz A; Pinon AC; Rossini AJ; Schantz S; Emsley L
    J Phys Chem B; 2018 Feb; 122(7):2073-2081. PubMed ID: 29332384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular-Level Structural Analysis of siRNA-Loaded Lipid Nanoparticles by
    Ueda K; Sakagawa Y; Saito T; Fujimoto T; Nakamura M; Sakuma F; Kaneko S; Tokumoto T; Nishimura K; Takeda J; Arai Y; Yamamoto K; Ikeda Y; Higashi K; Moribe K
    Mol Pharm; 2023 Sep; 20(9):4729-4742. PubMed ID: 37606988
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
    Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
    ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
    Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
    Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
    Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
    Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
    Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
    Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular trafficking kinetics of nucleic acid escape from lipid nanoparticles via fluorescence imaging.
    M Bailey-Hytholt C; Ulinski G; Dugas J; Haines M; Lazebnik M; Piepenhagen P; E Zarraga I; Bandekar A
    Curr Pharm Biotechnol; 2023 Apr; ():. PubMed ID: 37016519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells.
    Ferraresso F; Strilchuk AW; Juang LJ; Poole LG; Luyendyk JP; Kastrup CJ
    Mol Pharm; 2022 Jul; 19(7):2175-2182. PubMed ID: 35642083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo.
    Biscans A; Ly S; McHugh N; Cooper DA; Khvorova A
    J Control Release; 2022 Sep; 349():831-843. PubMed ID: 35917865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.